IDEXX Laboratories Quarterly Income Statement
NASDAQ: IDXXHealthcareDiagnostics & ResearchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
IDEXX Laboratories revenue and earnings
In the quarter ended Jun 30, 2026, IDEXX Laboratories generated $1.22 billion in revenue, up 9.7% from the same quarter a year earlier. Net income was $338.4 million (+15.1% year over year), for a net margin of 27.8% versus a median of 24.4% in the prior 5 quarters. Gross margin was 64.0% (up from 62.6%) and operating margin 35.0%.
Diluted earnings per share came in at $4.27, up from $3.63.
Summary generated from market data by MetaCap's automated system. Methodology
IDEXX Laboratories income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.22B | 1.14B | 1.09B | 1.11B | 1.11B | 998.43M | 954.29M | 975.54M | 1.00B | 964.10M | 901.60M | 915.53M |
| Revenue growth (YoY) | +9.66% | +14.26% | +14.28% | +13.29% | +10.55% | +3.56% | +5.84% | +6.56% | +6.35% | +7.10% | +8.81% | +8.78% |
| Cost of Revenue | 437.50M | 418.08M | 432.46M | 421.88M | 414.73M | 375.05M | 383.63M | 379.50M | 384.42M | 371.02M | 375.43M | 367.55M |
| Gross Profit | 779.09M | 722.74M | 658.11M | 683.35M | 694.73M | 623.38M | 570.66M | 596.04M | 619.16M | 593.07M | 526.17M | 547.98M |
| Operating Expenses | 353.52M | 360.15M | 342.51M | 328.51M | 321.69M | 306.85M | 308.97M | 292.15M | 355.36M | 294.11M | 280.87M | 272.70M |
| Research & Development | 65.43M | 65.79M | 66.83M | 63.41M | 61.90M | 59.06M | 57.73M | 53.98M | 55.45M | 52.63M | 51.81M | 47.97M |
| Selling, General & Admin | 288.09M | 294.37M | 275.68M | 265.09M | 259.79M | 247.78M | 251.25M | 238.17M | 299.91M | 241.48M | 229.05M | 224.73M |
| Operating Income | 425.57M | 362.59M | 315.61M | 354.85M | 373.05M | 316.53M | 261.69M | 303.89M | 263.80M | 298.96M | 245.30M | 275.28M |
| Interest Expense | 10.18M | 7.74M | 9.21M | 10.65M | 11.32M | 7.67M | 7.50M | 7.70M | 8.10M | 7.91M | 9.27M | 8.65M |
| Pretax Income | 417.22M | 355.44M | 306.98M | 344.77M | 362.35M | 310.08M | 256.39M | 298.91M | 259.06M | 295.48M | 239.67M | 267.89M |
| Income Tax | 78.81M | 77.00M | 58.79M | 70.16M | 68.36M | 67.41M | 40.24M | 66.07M | 55.76M | 59.90M | 45.15M | 55.66M |
| Net Income | 338.41M | 278.45M | 248.19M | 274.61M | 293.99M | 242.68M | 216.15M | 232.84M | 203.30M | 235.58M | 194.52M | 212.23M |
| Net Income growth (YoY) | +15.11% | +14.74% | +14.82% | +17.94% | +44.61% | +3.01% | +11.12% | +9.71% | -9.34% | +10.06% | +12.96% | +17.29% |
| EPS (Basic) | 4.29 | 3.50 | 3.10 | 3.43 | 3.66 | 2.98 | 2.64 | 2.83 | 2.46 | 2.84 | 2.34 | 2.55 |
| EPS (Diluted) | 4.27 | 3.47 | 3.09 | 3.40 | 3.63 | 2.96 | 2.62 | 2.80 | 2.44 | 2.81 | 2.31 | 2.53 |
| Shares Outstanding (Basic) | 78.95M | 79.65M | — | 80.10M | 80.41M | 81.32M | — | 82.30M | 82.63M | 83.10M | — | 83.10M |
| Shares Outstanding (Diluted) | 79.31M | 80.16M | — | 80.67M | 80.99M | 81.92M | — | 83.06M | 83.39M | 83.96M | — | 83.99M |
| EBITDA | 466.62M | 400.27M | 354.33M | 391.47M | 408.82M | 350.60M | 295.39M | 338.02M | 295.99M | 328.86M | 275.04M | 304.27M |
| Gross Margin | 64.04% | 63.35% | 60.35% | 61.83% | 62.62% | 62.44% | 59.80% | 61.10% | 61.70% | 61.52% | 58.36% | 59.85% |
| Operating Margin | 34.98% | 31.78% | 28.94% | 32.11% | 33.62% | 31.70% | 27.42% | 31.15% | 26.29% | 31.01% | 27.21% | 30.07% |
| Net Margin | 27.82% | 24.41% | 22.76% | 24.85% | 26.50% | 24.31% | 22.65% | 23.87% | 20.26% | 24.44% | 21.58% | 23.18% |
This table shows 12 quarterly periods of IDEXX Laboratories's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow IDXX's reporting calendar. What is a income statement?